THE WHO CEWG PROCESS AS UNIQUE OPPORTUNITY TO IMPLEMENT ALTERNATIVE R&D MODELS

Drugs for Neglected Disease initiative - DNDi
UAEM
The Hague- February 5 2016
OPPORTUNITY

• To Structurally & multilaterally address twofold problem:
  • Lack of innovation for non profitable markets (Ebola, Malaria, Zika)
  • High prices barring access to existing treatments
BACKGROUND

• ‘Intellectual property protection is not relevant for diseases where there is no profitable market’ CIPIH – 2003

• This was over 10 years ago. Now, we know that the current medical R&D system as a whole is not sustainable.
OVER 10-YEAR DISCUSSION AT WHA LEVEL TO FIND A SUSTAINABLE SOLUTION

2003
Resolution WHA56.27
Intellectual property rights, innovation and public health

Commission on Intellectual Property Rights, Innovation and Public Health

2006
Resolution WHA59.24
Public Health, innovation, essential health research and intellectual property rights: towards a global strategy and plan of action

Intergovernmental Working Group

2008
Resolution WHA61.21
Global strategy and plan of action on public health, innovation and intellectual property

Expert Working Group on Research and Development: Financing and Coordination

2010
Resolution WHA63.28
Establishment of a consultative expert working group on research and development: financing and coordination

Consultative Expert Working Group on Research and Development: Financing and Coordination

April 2016 WHO Open-ended meeting
CEWG RECOMMENDATIONS

• Negotiate Global Agreement on R&D

• 3 principles:
  • Open knowledge innovation
  • Equitable access licencing
  • De-linkage
Governments agree to experiment:

- Demonstration projects,
- Set up a global R&D observatory,
- Explore set up of pooled fund

Postpone to 2016: Global Agreement
THE GLOBAL BIOMEDICAL R&D FUND AND MECHANISM

Global Biomedical R&D Fund and Mechanism
For innovations of Public Health importance
governed by public leadership

Global Health R&D Observatory
Priority-Setting, Monitoring, Coordination

- AMR Initiatives
- Emerging Infections (incl. Ebola)
- Poverty Related / Neglected Diseases*

De-linkage
Open Innovation
Licensing for Access

...and others
WHAT’S HAPPENING NOW?

- Solutions & principles are there. nb
- Political will lacking

- Open Ended Meeting  April
- WHA 2016
WHAT SHOULD HAPPEN?

• Coordination between initiatives needed vs fragmentation
  ➢ Overarching agreement
• Broad Scope
• Apply key principles to anything going forward

- We need to scale up!
Joseph E. Stiglitz, Nobel Laureate, Member of the National Academy of Science, Corresponding Fellow, Royal Society.

Sir John Sulston, Nobel Laureate, Fellow of the Royal Society

Warren Kaplan, PhD, JD, MPH: Center for Global Health & Development/Boston University School of Public Health

Amy Kapczynski, JD, MA, MPhil, AB: Professor of Law; Faculty Director Global Health Justice Partnership, Yale Law Schoo

Benjamin Coriat, Professeur des Universités Faculté des Sciences Economiques. Université Paris 13. Sorbonne Paris Cité, France

Dean Baker, Co-Director, Center for Economic and Policy Research

Make Medicines for People Not for Profit
UAEM RnD Campaign

- **Why:** The need to change our RnD system
- **How:** Unite academics and researchers
- **What:** To push for political change
- **Where:** Globally
- **When:** 2016

Where do we stand now?